Medicare for All Act

The Medicare for All Act (HR3069) was introduced in the House of Representatives on April 29, 2025, by Rep. Jayapal and 112 cosponsors. It has since been referred to seven committees, including Energy and Commerce, Ways and Means, and Education and Workforce. This referral to multiple committees indicates the broad scope of the bill and the many areas of jurisdiction it touches, but also signals a complex and potentially lengthy legislative process. The bill is currently in the early stages of the legislative process. TheMedicare for All Act establishes a national health insurance program administered by the Department of Health and Human Services (HHS). This program would cover all U.S. residents and provide comprehensive medical services, including hospital services, prescription drugs, mental health, dental, vision, and long-term care, without cost-sharing. The bill explicitly states it would eliminate private health insurance, meaning there is no direct funding mechanism for private insurers. Instead, all healthcare spending would be federalized, representing a fundamental shift in how healthcare is financed in the United States. The bill does not specify an explicit funding amount, as it outlines a structural change to the healthcare system rather than a direct appropriation. Structural losers under this proposed legislation include private health insurers such as UnitedHealth Group ($UNH), CVS Health ($CVS), Humana Inc. ($HUM), The Cigna Group ($CI), Molina Healthcare, Inc. ($MOH), and Centene Corporation ($CNC), as their core business models would be eliminated. Pharmaceutical companies like Pfizer Inc. ($PFE), Johnson & Johnson ($JNJ), Merck & Co., Inc. ($MRK), and AbbVie Inc. ($ABBV) would also face significant pressure on their pricing power, as a single-payer system would likely negotiate drug prices more aggressively. The bill's comprehensive coverage, including prescription drugs, directly impacts the revenue streams of these companies. Recent market data for private health insurers shows varied performance over the last 30 days, with $UNH down -2.57%, $CVS down -6.88%, $CI down -1.98%, $MOH down -2.94%, and $CNC down -18.19%. Humana Inc. ($HUM) is an outlier with a 30-day change of +1.05%. Over the last 7 days, however, all these tickers have seen positive movement, ranging from +4.48% for $CVS to +11.32% for $CNC. Pharmaceutical companies have shown mixed 30-day performance: $PFE is up +4.58%, $JNJ is up +0.56%, $MRK is up +4.12%, while $ABBV is down -11.04%. The recent positive 7-day changes across many of these stocks suggest that the market is not currently pricing in significant immediate risk from this early-stage bill. The legislative path for HR3069 is extensive, requiring passage through multiple committees, a vote in the House, and then a similar process in the Senate before potentially reaching the President's desk. Given its early stage and the significant opposition it would likely face, the timeline for potential enactment is long and uncertain.